MycoLogics, Inc. Further Expands Antifungal Intellectual Property Portfolio
MycoLogics, Inc., an innovative biotechnology company specializing in the development of novel antifungal drugs and therapeutic and prophylactic vaccines, today announced the receipt of patent 6,730,495 and 6,743,598, awarded by the U.S. Patent and Trademark Office, for the discovery of compositions and methods related to both the identification of antimicrobial compounds and for the identification of fungal glucose utilization inhibitors and antifungal agents.
DENVER, CO (PRWEB) October 29, 2004 -- MycoLogics, Inc., an innovative
biotechnology company specializing in the development of novel antifungal drugs
and therapeutic and prophylactic vaccines, today announced the receipt of patent
6,730,495 and 6,743,598, awarded by the U.S. Patent and Trademark Office, for
the discovery of compositions and methods related to both the identification of
antimicrobial compounds and for the identification of fungal glucose utilization
inhibitors and antifungal agents.
Infections by fungal or bacterial
species account for significant morbidity and mortality throughout the world.
Although significant resources have been dedicated to identifying compounds
having antimicrobial properties, microbial infections continue to present a
significant human health risk in both developed and underdeveloped countries.
Patent 6,730,495 allows for an assay of ketol-isomerase activity to be utilized
for screening potential drug compounds that possess antimicrobial activity via
the inhibition of this enzyme’s activity.
During the last three decades
there has been a dramatic increase in the frequency of fungal infections,
especially disseminated systemic mycoses in immunocompromised patients. Patent
6,743,598 finds use in deriving new classes of antifungal drug compounds that
have the ability to inhibit fungal glucose utilization by affecting the
production of key metabolic intermediates.
“These patents are key in our
proprietary antifungal drug discovery program. They provide the unique
opportunity for these assays to be used to screen compound libraries for
inhibitors of ketol-isomerase and glycolytic enzyme activities,” said Dr. Claude
P. Selitrennikoff, Ph.D., President and Chief Executive Officer of MycoLogics,
Inc.
About MycoLogics, Inc.
MycoLogics, Inc. is an innovative
biotechnology company specializing in the development of novel antifungal drugs
and therapeutic and prophylactic vaccines against human fungal and parasitic
pathogens, the discovery and isolation of novel antifungal compounds for
therapeutic use, and the development of novel high throughput assays that target
components of fungal cell walls. MycoLogics, Inc. is headquartered in Aurora, CO
at the Fitzsimmons Colorado Bioscience Park. For more information please visit
www.mycologics.com.
CONTACT INFORMATION:
Dr. Claude
P. Selitrennikoff, Ph.D.
President and CEO
MycoLogics, Inc.
Colorado
Bioscience Park
12635 East Montview Blvd., Suite 131
Aurora, CO
80010
Tel: (303) 548-5017
Fax: (303) 724-0861
e-mail protected from
spam bots
# # #
Source : http://www.prweb.com/releases/2004/10/prweb172500.htm